Abstract
Patients with multiple sclerosis (MS) often suffer from cognitive dysfunction; the underlying mechanisms have not been fully elucidated. Recent studies suggest that MS leads to heightened synaptic transmission and plasticity in different brain areas, and therefore may contribute to the observed behavioral abnormalities. Recent findings demonstrate synaptic plasticity changes in MS, including evidence from animal models of experimental autoimmune encephalomyelitis and human MS patients.
Keywords: Experimental autoimmune encephalomyelitis, inflammation, multiple sclerosis, N-methyl-D-aspartic acid, synaptic plasticity, trophic factor.
CNS & Neurological Disorders - Drug Targets
Title:Commentary (Changes of Synaptic Plasticity in Multiple Sclerosis)
Volume: 14 Issue: 2
Author(s): Ti-Fei Yuan, Chunlei Shan and Oscar Arias-Carrion
Affiliation:
Keywords: Experimental autoimmune encephalomyelitis, inflammation, multiple sclerosis, N-methyl-D-aspartic acid, synaptic plasticity, trophic factor.
Abstract: Patients with multiple sclerosis (MS) often suffer from cognitive dysfunction; the underlying mechanisms have not been fully elucidated. Recent studies suggest that MS leads to heightened synaptic transmission and plasticity in different brain areas, and therefore may contribute to the observed behavioral abnormalities. Recent findings demonstrate synaptic plasticity changes in MS, including evidence from animal models of experimental autoimmune encephalomyelitis and human MS patients.
Export Options
About this article
Cite this article as:
Yuan Ti-Fei, Shan Chunlei and Arias-Carrion Oscar, Commentary (Changes of Synaptic Plasticity in Multiple Sclerosis), CNS & Neurological Disorders - Drug Targets 2015; 14 (2) . https://dx.doi.org/10.2174/1871527313666141114203620
DOI https://dx.doi.org/10.2174/1871527313666141114203620 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Cannabinoids and Neuroprotection in Motor-Related Disorders
CNS & Neurological Disorders - Drug Targets Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function
Current Neuropharmacology Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Integrating the Universe of Effector and Regulatory Immune Cell Subsets: An Emerging Role of Protein-Glycan Interactions
Current Immunology Reviews (Discontinued) mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Neuroinflammation and Neuroprotection: An Update on (Future) Neurotrophin-Related Strategies in Multiple Sclerosis Treatment
Current Medicinal Chemistry Editorial (Thematic Issue: GABAergic Modulation as Treatment Strategy: Consideration of Several Diseases)
Current Pharmaceutical Design Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
Current Pharmaceutical Design Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Neuroprotection: The Emerging Concept of Restorative Neural Stem Cell Biology for the Treatment of Neurodegenerative Diseases
Current Neuropharmacology Efficient Expression and Purification of Recombinant Therapeutic Protein Candidates, Human Midkine and Pleiotrophin
Current Pharmaceutical Biotechnology CypD: The Key to the Death Door
CNS & Neurological Disorders - Drug Targets Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Use of Kv1.3 Blockers for Inflammatory Skin Conditions
Current Medicinal Chemistry